- Conditions
- Tourette's Syndrome, Chronic Motor Tic Disorder, Chronic Motor Vocal Disorder
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 9,249
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Non-syndromic Retinitis Pigmentosa
- Interventions
- Gene therapy: GS030-DP AND Medical device: GS030-MD
- Combination Product
- Lead sponsor
- GenSight Biologics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Sickle Cell Disease
- Interventions
- Prasugrel, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 20
- States / cities
- Oakland, California • Palo Alto, California • Hartford, Connecticut + 16 more
- Conditions
- Cystic Fibrosis
- Interventions
- urine lipoarabinomannan (LAM)
- Diagnostic Test
- Lead sponsor
- Jerry A. Nick, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Metabolic Syndrome, Diabetes Mellitus, Type 2, Obesity
- Interventions
- Not listed
- Lead sponsor
- Eric Hoffman
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Juvenile Myelomonocytic Leukemia, Mucositis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- supersaturated calcium phosphate rinse, placebo, questionnaire administration, quality-of-life assessment
- Drug · Other · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 31
- States / cities
- Arcadia, California • Duarte, California • Oakland, California + 26 more
- Conditions
- Hypogonadotropic Hypogonadism, Reproductive Disorder, Kallmann Syndrome, Delayed Puberty
- Interventions
- Not listed
- Lead sponsor
- Stephanie B. Seminara, MD
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 854 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Afatinib Dimaleate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cystic Fibrosis, Fatigue
- Interventions
- CF Wellness Program Sessions
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Seattle, Washington
- Conditions
- Opioid Sensitivity, Individual Difference, Abuse Opioids
- Interventions
- Within-subject test of blinded study medication
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- Not listed
- Lead sponsor
- Shire
- Industry
- Eligibility
- Not listed
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 20 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Deflazacort
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 4 Years to 16 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Chicago, Illinois • Rochester, New York + 1 more
- Conditions
- Galactosialidosis
- Interventions
- Not listed
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 6 Months and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Solid Tumors
- Interventions
- Cobimetinib, Pictilisib
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 6
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 2 more
- Conditions
- Muckle Wells Syndrome
- Interventions
- ACZ885, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 4 Years to 75 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 3
- States / cities
- San Francisco, California • Chicago, Illinois • Madison, Wisconsin
- Conditions
- Primary Immunodeficiency
- Interventions
- Gadolinium For abdomen, Gadolinium For lower back, Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, Efficacy of Gammagard subcutaneously at Week 36, Efficacy of Gammagard subdermally at Week 36, Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, Adverse Reactions of Gammagard subcutaneously at Week 36, Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, Adverse Reactions of Gammagard subdermally at Week 36
- Drug
- Lead sponsor
- ASIS Corporation
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Westminster, California
- Conditions
- Retinitis Pigmentosa Associated With CNGB1 Mutations
- Interventions
- No intervention, this is a natural history progression study
- Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 2
- States / cities
- New York, New York • Philadelphia, Pennsylvania
- Conditions
- Myopia
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 4 Years and older
- Enrollment
- 851 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- CF Therapeutics Development Network Coordinating Center
- Network
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Iowa City, Iowa • Chapel Hill, North Carolina
- Conditions
- Becker Muscular Dystrophy
- Interventions
- (-)-epicatechin
- Drug
- Lead sponsor
- Craig McDonald, MD
- Other
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Glycogen Storage Disease Type II
- Interventions
- avalglucosidase alfa
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 0 Days to 12 Months
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 6
- States / cities
- Stanford, California • Minneapolis, Minnesota • Hawthorne, New York + 3 more
- Conditions
- Neurofibromatosis, MPNST
- Interventions
- MRI, FDG-PET/CT scans, [18F]-FLT-PET/CT scans
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 10 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Arrhythmia, Cardiovascular Diseases, Heart Failure, CVD
- Interventions
- Not listed
- Lead sponsor
- CardioDx
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1,564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 8
- States / cities
- Anchorage, Alaska • Palo Alto, California • Minneapolis, Minnesota + 5 more
- Conditions
- Atopic Dermatitis
- Interventions
- Clobetasol propionate 0.05% Topical Oil
- Drug
- Lead sponsor
- Hill Dermaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 6
- States / cities
- Sanford, Florida • Savannah, Georgia • Philadelphia, Pennsylvania + 3 more